Disease State

Lung Cancer

Title

ERBB Family Blockade in NSCLC: Expert Perspectives on Optimizing Management - Denver, CO

Event Date/Time

Wednesday, September 9, 2015 | 6:30 AM - 8:00 AM

Location

Location

Colorado Convention Center - Room 601/603
700 14th Street
Denver, CO 80202
United States

Faculty

Faculty

Barbara J. Gitlitz, MD - Chair
Associate Professor of Medicine
University of Southern California
Norris Comprehensive Cancer Center
Los Angeles, California

Geoffrey R. Oxnard, MD
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Anne S. Tsao, MD
Associate Professor
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
Department of Thoracic/Head & Neck Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Helena Yu, MD
Assistant Professor
Memorial Sloan Kettering Cancer Center
New York, New York

Target Audience

The target audience for this activity is medical oncologists, hematologist/oncologists, surgeons, radiation oncologists, pathologists, oncology pharmacists, oncology nurses, and other allied healthcare professionals caring for patients with NSCLC.

Educational Objectives

At the conclusion of this activity, participants should be able to:

  • Utilize testing for identifying predictive molecular markers and driver mutations in NSCLC patients to aid in therapy individualization
  • Review the role of ERBB family blockade in NSCLC, describing its clinical implications and mechanisms of resistance
  • Critically analyze current and emerging therapeutic strategies for EGFR mutation-positive NSCLC and contemporary strategies for managing patients with acquired resistance including the role and clinical outcomes with irreversible ERBB family blockade
  • Increase awareness of recent and ongoing clinical trials in patients with advanced NSCLC with actionable mutations

 

PHYSICIAN CONTINUING EDUCATION

PHYSICIAN CONTINUING EDUCATION

Accreditation Statement
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Educational Concepts Group, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION

PHARMACIST CONTINUING EDUCATION

Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Educational Concepts Group, LLC designates this continuing education activity for 1.0 contact hour (0.10 CEU) (UAN 0199-0000-15-018-L01-P).

Type of activity: Application-based

CME/CE CREDIT

There are no fees for participating and receiving CME/CE credits for this activity. Participants who complete an activity evaluation form and return it to Educational Concepts Group, LLC may view and print their credit letter or statement of credit via the website, www.ecgcme.com, 6 weeks after the activity.

FACULTY DISCLOSURE STATEMENT

FACULTY DISCLOSURE STATEMENT

All faculty participating in continuing education activities provided by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.

REGISTRATION DETAILS

REGISTRATION DETAILS

Registration before Friday, September 4, 2015 is requested. You will receive confirmation of your registration by e-mail. On-site registration is limited to space availability.

REGISTRATION FEE: NONE

Questions?

Please contact Tricia Watkins at Educational Concepts Group, LLC
Phone: 1.866.984.5186 | Fax: 1.404.994.2779 | Contact Us

AMERICANS WITH DISABILITIES ACT (ADA)

AMERICANS WITH DISABILITIES ACT (ADA)

ECG staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Tricia Watkins prior to the live event at 1.866.984.5186.

This activity is provided by Educational Concepts Group, LLC.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

This activity was approved by the 16th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the 16th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by IASLC.